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L-Glutamic acid (L-Glu, Figure 1) is the main excitatory 
neurotransmitter in the central nervous system (CNS), where it is 
involved in the modulation of many physiological processes such 
as learning, memory, and synaptic plasticity.1 Once released from 
the presynaptic neurons into the glutamatergic synaptic cleft, L-
Glu activates two main classes of receptors: G-protein-coupled 
metabotropic Glu receptors (mGluRs) and ligand-gated 
ionotropic Glu receptors (iGluRs). On the basis of the agonist 
selectivity, iGluRs have been named N-methyl-D-aspartic acid 
(NMDA) receptors, (RS)-2-amino-3-(3-hydroxy-5-methyl-4-
isoxazolyl)propionic acid (AMPA) receptors, and kainic acid 
(KA) receptors.1-5 
For many years now, we have been actively involved in the 
search for new selective NMDA antagonists, and we have 
successfully designed a number of ligands, some of which 
showed promising neuroprotective activity.6-14 NMDA 
antagonists are typically characterized by an increase in the 
distance between the proximal and the distal acidic groups of 
Glu, e.g. 4-6 carbon atoms. The simplest example of a Glu higher 
homologue behaving as a NMDA antagonist is (R)-aminoadipic 
acid [(R)-AA, Figure 1]. The amino acid skeleton may also be 
incorporated into a cyclic structure to decrease the 
conformational freedom (Figure 1). It is worth pointing out that 
the eutomer of the majority of NMDA ligands possesses the R 
configuration of the α amino acidic stereogenic center, at 
variance with the endogenous ligand (L-Glu).  
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Figure 1. Structures of L-Glu, (R)-AA and some NMDA 
antagonists. 
In the present paper, we exploited a Heck reaction to easily 
generate compounds (R)-5 and (R)-6 (Figure 2), and the 
corresponding saturated derivatives (R)-7 and (R)-8, which are 
characterized by the R configuration at the amino acid 
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A convenient synthesis of four new enantiomerically pure acidic amino acids is reported and 
their affinity at ionotropic glutamate receptors is analyzed. The new compounds are higher 
homologues of glutamic acid in which the molecular complexity has been increased by 
introducing an aromatic/heteroaromatic ring, i.e. a phenyl or a thiophene ring, that could give 
additional electronic interactions with the receptors. The results of the present investigation 
indicate that the insertion of an aromatic/heteroaromatic ring into the amino acid skeleton of 
glutamate higher homologues is well tolerated and this modification could be exploited to 
generate a new class of NMDA antagonists. 
2009 Elsevier Ltd. All rights reserved. 
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stereocenter and by a six-carbon-atom spacer between the 
proximal and the distal acidic groups, therefore matching the 
requirements needed to generate NMDA antagonists. The 
aromatic ring, i.e. a phenyl or a thiophene ring, can give 
additional electronic interactions with the binding pocket, which 
could strengthen the affinity for the target receptor. In addition, 
this moiety could be exploited to further decorate the molecule, 
in order to increase the binding affinity. 
 
 
 
 
 
 
 
Figure 2. Structures of the synthesized compounds. 
The key step to obtain the planned compounds is the Heck 
reaction between conveniently protected D-allyglycine (R)-9 and 
the appropriate aryl halide, i.e. methyl 2-iodobenzoate 10 or 
methyl 4-bromothiophene-3-carboxylate 12. D-allyglycine is 
commercially available but it is very expensive (about 700 
euro/g). Therefore, we prepared the racemic alkene (RS)-9, with a 
conventional procedure, by reacting allyl bromide with diethyl 
acetamidomalonate,16,17 and then we developed a suitable method 
for its chromatographic resolution with a semi-preparative chiral 
HPLC column (Scheme 1). An excellent enantiomeric separation 
(α = 4.2; Rs = 10.2) was achieved with a column containing tris-
(2-methyl-5-chloro-phenyl)carbamoyl amylose as the stationary 
phase, affording (−)-9 as the first fraction and (+)-9 as the second 
fraction. The absolute configuration was assigned to each 
enantiomer on the basis of the optical activity, by comparison 
with that reported in the literature.18 Intermediates 10 and 12 were 
easily obtained, in quantitative yield, by esterification of the 
corresponding commercially available carboxylic acid with 
methanol in the presence of SOCl2. 
 
 
 
 
 
 
Scheme 1.Synthesis of the enantiopure alkenes (R)-9and (S)-
9. 
The Heck reaction was optimized, in terms of catalyst, base, 
solvent, temperature and reaction time, for each aryl halide. 
Using methyl 2-iodobenzoate 10, the best yield was achieved 
performing the reaction in acetonitrile and using palladium 
acetate as a catalyst and diisopropylamine (DIPEA) as a base 
(Scheme 2). A good yield (75%) was obtained by refluxing the 
reaction mixture for 24 hours. Interestingly, a similar result can 
be obtained after only two hours, by heating the reaction mixture 
in a microwave reactor at 110 °C. As expected, we isolated only 
one stereoisomer to which we assigned the E configuration by 
taking into account the high value of the 1H NMR coupling 
constant (J = 16.0 Hz) between the two olefinic protons. 
Unfortunately, by applying the same reaction conditions to 
methyl 4-bromothiophene-3-carboxylate 12, we isolated the 
desired product (R)-13 in only 15% yield. In this case, the use of 
Tetrakis(triphenylphosphine)-palladium and sodium acetate in 
DMF, under conventional heating at 110 °C for 18 hours, 
produced intermediate (R)-13 in excellent yield (81%) (Scheme 
2). The use of the microwave heating, even at lower temperature, 
resulted in a lower yield and purity. 
 
 
 
 
 
 
 
Scheme 2. Reagents and conditions: a) Pd(OAc)2, DIPEA, 
CH3CN, µW, 130 °C, 2h; b) Tetrakis(triphenylphosphine)-
palladium, NaOAc, DMF, 110 °C, 18 h. 
Part of intermediates (R)-11 and (R)-13 were catalytically 
hydrogenated in the presence of 5% Pd/C to yield the saturated 
derivatives (R)-14 and (R)-15, respectively (Scheme 3). Final 
amino acids (R)-5-8 were obtained by alkaline hydrolysis of the 
ester functions followed by treatment with a 30% solution of 
trifluoroacetic acid in dichloromethane to remove the N-Boc 
protective group (Scheme 3). 
 
 
 
 
 
 
 
 
 
Scheme 3. Reagents and conditions: a) H2, Pd/C 5%, MeOH; 
b) NaOH 1N, MeOH; c) 30% TFA, CH2Cl2. 
The new derivatives were submitted to in vitro assays, 
evaluating receptor binding in rat cortical membranes, using 
radioligands [3H]CGP39653, [3H]AMPA, and [3H]KA for 
NMDA, AMPA, and KA receptors, respectively (Table 1).19-21 
Table 1. Receptor binding affinities at native rat iGluRs.[a] 
Compound 
[3H]AMPA 
IC50 (μM) 
[3H]KAINIC50 
(μM) 
[3H]CGP39653Ki 
(μM) 
(R)-5 > 100 > 100 > 100 
(R)-6 > 100 > 100 52 [4.290.04] 
(R)-7 > 100 > 100 32 [4.490.04] 
(R)-8 > 100 > 100 14 [4.860.05] 
(R)-AA[b] nd nd 13 
[a] Data are given as mean mean pKi  SEM of three 
independent experiments. [b] Data from ref. 22 
Three out of the four tested compounds bound to NMDA 
receptor, with (R)-8 having the best affinity (Ki = 14 μM). 
Interestingly, the Ki value of (R)-8 is almost identical to that of 
(R)-AA, our reference NMDA antagonist. The outcome of the 
present investigation indicates that a reduction in the 
conformational flexibility of aminoadipic acid through the 
insertion of an aromatic/heteroaromatic ring is well tolerated by 
NMDA receptors. This result opens the possibility to further 
increase the interactions with the binding pocket through 
appropriate decorations of the aromatic/heteroaromatic ring thus 
generating novel NMDA antagonists provided with high potency 
and, hopefully, subtype selectivity. As an added value, the 
synthetic route leading to this new class of ligands is fast, cheap 
and versatile, since library of derivatives can be easily obtained 
by simply varying the nature of the aryl/heteroaryl halide. 
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